+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Antisense Oligonucleotide"

From
From
From
From
Antisense and RNAi Therapeutics Market - Product Thumbnail Image

Antisense and RNAi Therapeutics Market

  • Report
  • March 2024
  • 200 Pages
  • Global
From
RNA-based Therapeutics Market - Product Thumbnail Image

RNA-based Therapeutics Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Exosomes Market Analysis & Forecast To 2024-2034 - Product Thumbnail Image

Exosomes Market Analysis & Forecast To 2024-2034

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Viral Vector Vaccines Market Report and Forecast 2024-2032 - Product Thumbnail Image

Viral Vector Vaccines Market Report and Forecast 2024-2032

  • Report
  • September 2023
  • 160 Pages
  • Global
From
From
Loading Indicator

The Antisense Oligonucleotide market is a segment of the biotechnology industry that focuses on the development of drugs that use short strands of nucleic acids to target and inhibit the expression of specific genes. These drugs are used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Antisense oligonucleotides are designed to bind to a specific mRNA sequence, blocking the translation of the gene into a protein. This technology has the potential to revolutionize the treatment of many diseases, as it can be used to target specific genes without affecting other parts of the body. The Antisense Oligonucleotide market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Arrowhead Pharmaceuticals. Other companies in the market include Regulus Therapeutics, Dicerna Pharmaceuticals, and Quark Pharmaceuticals. Show Less Read more